A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers

Clinical trial NCT05024747 · COMPLETED

Trial details

NCT number: NCT05024747
Sponsor: HALEON
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Tobacco Use Disorder

Start date: 2021-09-01
Primary completion: 2021-10-25
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.